Hyperinsulinemia Influences the Short-Term Efficiency of Laparoscopic Sleeve Gastrectomy for Patients with Obesity and Insulin Resistance

References

• Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1923–1994.
   PubMed Web of Science ®Google Scholar
• Grönroos S, Helmiö M, Juuti A, et al. Effect of laparoscopic sleeve gastrectomy vs roux-en-y gastric bypass on weight loss and quality of life at 7 years in patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2021;156(2):137–146. doi:10.1001/jamasurg.2020.5666
   PubMed Web of Science ®Google Scholar
• Angrisani L, Santonicola A, Iovino P, Ramos A, Shikora S, Kow L. Bariatric surgery survey 2018: similarities and disparities among the 5 IFSO chapters. Obes Surg. 2021;31(5):1937–1948. doi:10.1007/s11695-020-05207-7
   PubMed Web of Science ®Google Scholar
• Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA. 2018;319(3):241–254. doi:10.1001/jama.2017.20313
   PubMed Web of Science ®Google Scholar
• Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA. 2018;319(3):255–265. doi:10.1001/jama.2017.20897
   PubMed Web of Science ®Google Scholar
• Zhang A, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes Metab J. 2021;45(3):285–311. doi:10.4093/dmj.2020.0250
   PubMed Web of Science ®Google Scholar
• Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes. 2000;49(12):2094–2101. doi:10.2337/diabetes.49.12.2094
   PubMed Web of Science ®Google Scholar
• Templeman NM, Clee SM, Johnson JD. Suppression of hyperinsulinaemia in growing female mice provides long-term protection against obesity. Diabetologia. 2015;58(10):2392–2402. doi:10.1007/s00125-015-3676-7
   PubMed Web of Science ®Google Scholar
• Xiao-yan X, Wwn-ying Y, Zhao-jun Y. The diagnostic significance of homeostasis model assessment of insulin resistance in metabolic syndrome among subjects with different glucose tolerance. Chin J Diabetes. 2004;12(3):182–186.
   Google Scholar
• Moorehead MK, Ardelt-Gattinger E, Lechner H, Oria HE. The validation of the Moorehead-ardelt quality of life questionnaire II. Obes Surg. 2003;13(5):684–692. doi:10.1381/096089203322509237
   PubMed Web of Science ®Google Scholar
• Brethauer SA, Kim J, El Chaar M, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Obes Surg. 2015;25(4):587–606. doi:10.1007/s11695-015-1645-3
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213. doi:10.1097/01.sla.0000133083.54934.ae
   PubMed Web of Science ®Google Scholar
• Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–223. doi:10.1038/s41573-021-00337-8
   PubMed Web of Science ®Google Scholar
• Kolb H, Stumvoll M, Kramer W, Kempf K, Martin S. Insulin translates unfavourable lifestyle into obesity. BMC Med. 2018;16(1):232. doi:10.1186/s12916-018-1225-1
   PubMedGoogle Scholar
• Vecchio I, Tornali C, Bragazzi NL, Martini M. The discovery of insulin: an important milestone in the history of medicine. Front Endocrinol. 2018;9:613. doi:10.3389/fendo.2018.00613
   PubMed Web of Science ®Google Scholar
• Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022;7(1):216. doi:10.1038/s41392-022-01073-0
   PubMed Web of Science ®Google Scholar
• Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576(7785):51–60. doi:10.1038/s41586-019-1797-8
   PubMed Web of Science ®Google Scholar
• Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013;7(1):14–24. doi:10.1007/s11684-013-0262-6
   PubMed Web of Science ®Google Scholar
• Guo L, Luo W, Tan T, et al. Early-phase insulin hypersecretion associated with weight loss outcome after LSG: a prospective cohort study in Asian patients with BMI ≥28 kg/m(2). Surg Obes Relat Dis. 2022;18(10):1209–1217. doi:10.1016/j.soard.2022.05.013
   PubMed Web of Science ®Google Scholar
• Pedersen DJ, Guilherme A, Danai LV, et al. A major role of insulin in promoting obesity-associated adipose tissue inflammation. Mol Metab. 2015;4(7):507–518. doi:10.1016/j.molmet.2015.04.003
   PubMed Web of Science ®Google Scholar
• Templeman NM, Skovsø S, Page MM, Lim GE, Johnson JD. A causal role for hyperinsulinemia in obesity. J Endocrinol. 2017;232(3):R173–R183. doi:10.1530/JOE-16-0449
   PubMed Web of Science ®Google Scholar
• Kim MK, Reaven GM, Kim SH. Dissecting the relationship between obesity and hyperinsulinemia: role of insulin secretion and insulin clearance. Obesity. 2017;25(2):378–383. doi:10.1002/oby.21699
   PubMed Web of Science ®Google Scholar
• Jansen HJ, Stienstra R, van Diepen JA, et al. Start of insulin therapy in patients with type 2 diabetes mellitus promotes the influx of macrophages into subcutaneous adipose tissue. Diabetologia. 2013;56(12):2573–2581. doi:10.1007/s00125-013-3018-6
   PubMed Web of Science ®Google Scholar
• Skovsø S, Damgaard J, Fels JJ, et al. Effects of insulin therapy on weight gain and fat distribution in the HF/HS-STZ rat model of type 2 diabetes. Int J Obes. 2015;39(10):1531–1538. doi:10.1038/ijo.2015.92
   Web of Science ®Google Scholar
• Lustig RH, Greenway F, Velasquez-Mieyer P, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes. 2006;30(2):331–341. doi:10.1038/sj.ijo.0803074
   Web of Science ®Google Scholar
• Esler M, Lambert G, Schlaich M, Dixon J, Sari CI, Lambert E. Obesity paradox in hypertension: is this because sympathetic activation in obesity-hypertension takes a benign form. Hypertension. 2018;71(1):22–33. doi:10.1161/HYPERTENSIONAHA.117.09790
   PubMed Web of Science ®Google Scholar
• da Silva AA, Do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited. Can J Cardiol. 2020;36(5):671–682. doi:10.1016/j.cjca.2020.02.066
   PubMed Web of Science ®Google Scholar
• Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1–7. doi:10.1016/j.phrs.2017.05.013
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension. 1983;5(1):86–99. doi:10.1161/01.HYP.5.1.86
   PubMed Web of Science ®Google Scholar